<DOC>
	<DOCNO>NCT00683462</DOCNO>
	<brief_summary>A 3-way cross-over trial two week treatment three drug condition . AZD3480 give dos ( A ) 5mg/day , ( B ) 50 mg/day ( C ) placebo 24 non-smoking adult DSM-IV confirm ADHD . Three week washout treatment period . CYP2D6 genotyping complete screen slow metabolisers exclude participation study . Cognitive , ADHD symptom , safety pharmacokinetic ( PK ) assessment make treatment period . Safety tolerability assessment major component trial serious adverse event ( SAE ) immediately ( within 24 hour ) report Targacept AstraZenca .</brief_summary>
	<brief_title>An Exploratory Trial AZD3480 ( TC-1734 ) Treatment Adult Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>Confirmed diagnosis DSMIV ADHD Score equal 2 least six nine item least one subscales ConnorÂ´s Adult ADHD Rating Scale ( CAARSINV ) Score equal 4 ( least moderate severity ) Clinical Global ImpressionsSeverity ( CGIS ) test Current DSMIV Axis I psychiatric disorder ( ADHD ) Current user cigarette nicotinecontaining product . Slow metabolizers indicate CYP2D6 genotyping . Use drug affect cognitive function within 8 week prior enrollment visit intend use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>